Heart failure & cardiomyopathies
Transcatheter Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy: A Multicenter Propensity Score-Based Analysis
Authors' conclusion
After 5 years of follow-up, CA did not improve major adverse cardiac outcomes in a large cohort of patients with HCM and AF.
Study context
- Population
- Patients with hypertrophic cardiomyopathy and atrial fibrillation (AF)matched cohort n = 226
- Participants
- 555 patients
- Exposure
- Catheter ablation vs medical therapy for AF
- Interventionn = 113
- Medicaln = 113reference
- Outcome
- Composite of:
- All-cause mortality
- Heart transplant
- Acute HF exacerbations
- Follow-up
- Median 58.1 months
Methodological detailsmulticentre, propensity-score matched, inverse probability weighted analysis
- Multicentre
- Propensity-score matched
- Inverse probability weighted analysis
Main finding
As reported in the abstract
P = 0.9
Observational data: associations, not effects.
Secondary outcomes
AF recurrence
P = 0.001
Transition to permanent AF
P = 0.026
| Outcome | Intervention | Medical | P value |
|---|---|---|---|
| Major arrhythmic events | 4.4 | 8.0% | P = 0.779 |
Safety
Thromboembolic stroke
P = 0.144
| Outcome | Intervention | Medical |
|---|---|---|
| Severe complications related to CAUncommon | 0.7% | — not stated in the abstract |
— not stated in the abstract
Original publication
Transcatheter Ablation of Atrial Fibrillation in Patients With Hypertrophic Cardiomyopathy: A Multicenter Propensity Score-Based Analysis. JACC Adv. Published 15 March 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →